Nothing said here yet.
to join the conversation.
CRANBURY, N.J., October 15, 2026--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated commercial-stage biotechnology company advancing genetic medicines for rare and life-threatening diseases, focused on inherited cardiovascular disorders, today…
Rocket Pharmaceuticals (NASDAQ: RCKT) shares rose 4% on Wednesday after the biotechnology company secured access to up to $150 million under a credit facility with Hercules Capital.
CRANBURY, N.J., October 07, 2026--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated commercial-stage biotechnology company advancing genetic medicines for rare and life-threatening diseases, highlighted key findings and development milestones…
Under the terms of the agreement, Rocket drew an initial $35m upon closing.
Rocket Pharmaceuticals (NASDAQ:RCKT) outlined updated clinical, regulatory and commercial plans for its investigational gene therapy RP-A501 in Danon disease, reporting longer-term Phase I findings, preliminary Phase II observations and an FDA-aligned pivotal…
CRANBURY, N.J., October 06, 2026--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing genetic medicines for rare and life-threatening diseases, focused on inherited cardiovascular disorders, today…
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) said September 15 that the FDA agreed to count three patients treated under the modified RP-A501 protocol toward the pivotal Phase 2 efficacy cohort of 12 male patients.
Needham said the FDA outcome was better than expected because the regulator could have demanded meaningful changes to Rocket’s Danon disease trial.
Rocket Pharmaceuticals (NASDAQ:RCKT) shares rose 8% on Tuesday after the company said it reached alignment with the US Food and Drug Administration on the pivotal Phase 2 trial of RP-A501 for Danon disease.
The FDA confirmed continued enrollment and dosing under the modified trial protocol after reviewing safety data from the first three patients treated at the recalibrated dose.
CRANBURY, N.J., September 15, 2026--Rocket Pharmaceuticals, Inc.
Rocket Pharmaceuticals (RCKT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.